Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Mycotechnology Inc. maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently features 2 pending office actions, which are distributed across 2 distinct examiners. This distribution means that the company must manage the individual preferences and review styles of 2 distinct examiners simultaneously. Despite this variety of examiners, all current activity is concentrated within 1 distinct art unit, suggesting a strong technical focus for the company's innovations.
KARUNASENA, ENUSHA is the busiest examiner for the portfolio, currently managing 1 busiest examiner pending action. Since there are 2 pending office actions in total, the workload is spread across the 2 distinct examiners, with no single individual handling more than 1 action. For patent practitioners, the concentration of 2 distinct examiners within 1 distinct art unit is notable, as it provides a consistent procedural framework while requiring an adaptable strategy for different reviewers. The presence of 1 distinct art unit simplifies the administrative landscape by limiting the procedural rules to those of a single group. This combination of examiner diversity and art unit concentration defines the current prosecution environment for Mycotechnology Inc.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KARUNASENA, ENUSHA | 1 | 0.0% | +0.0% |
| AFREMOVA, VERA | 1 | 50.5% | +29.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566975 | METHODS FOR THE PRODUCTION OF MYCELIAL BIOMASS FROM DATE EXTRACT | KARUNASENA, ENUSHA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17642328 | METHODS FOR REDUCTION OF BITTERNESS IN CANNABINOIDS USING MYCELIAL MATERIALS | AFREMOVA, VERA | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1653 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566975 | METHODS FOR THE PRODUCTION OF MYCELIAL BIOMASS FROM DATE EXTRACT | KARUNASENA, ENUSHA | 1653 | §103§112 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 17642328 | METHODS FOR REDUCTION OF BITTERNESS IN CANNABINOIDS USING MYCELIAL MATERIALS | AFREMOVA, VERA | 1653 | §103 | Non-Final OA | 17d overdue | Pending | Mar 11, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial